Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study Background: Many persons who attempt to quit smoking have made previous unsuccessful attempts to quit with pharmacologic aids. An understanding of the impact of these previous attempts to quit is vital for selecting medications that may be more successful in a future attempt to quit. In particular, the effect of repeated use of bupropion SR (Zyban; INN, amfebutamone) on abstinence rates has not been studied previously. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study in 450 smokers who had previously used bupropion in a smoking cessation attempt. The study consisted of a screening phase, a 12-week treatment phase, and a follow-up at month 6. Participants made regular clinic visits throughout the treatment phase during which they received brief counseling sessions to encourage abstinence from smoking. The primary end point was continuous abstinence from smoking from weeks 4 through 7. Secondary efficacy end points were examined throughout the treatment phase and at follow-up after 6 months. Results: In participants receiving bupropion SR, 27% (61 of 226) remained abstinent throughout the period from weeks 4 through 7 compared with 5% (11 of 224) of participants receiving placebo (P < .001). Significantly (P < .001) more participants who received bupropion SR during the treatment phase remained continuously abstinent from the start of week 4 through month 6 (27 of 226; 12%) compared with participants who received placebo (5 of 224; 2%). Eleven participants receiving placebo (5%) and 19 participants receiving bupropion SR (8%) stopped taking the study medication because of an adverse event. The majority of smokers who attempt to stop smoking are unsuccessful in stopping or they relapse within 1 year. 1 The availability of nicotine replacement (nicotine replacement therapy) products over the counter and prescription bupropion hydrochloride sustained release (Zyban; INN, amfebutamone) has resulted in more smokers attempting to quit smoking with the assistance of a pharmacologic aid. National guidelines for smoking cessation now recommend the use of a pharmacologic aid coupled with behavioral therapy for all smokers attempting to quit smoking. 2 An understanding of the efficacy of pharmacologic treatments used in previous cessation attempts is therefore vital for selecting medications that may be more successful in a future
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CLINICAL TRIALS
attempt. Little is reported about the efficacy of medication retreatment for smokers unable to quit or those who relapse after a period of abstinence. Available evidence 3 shows that retreatment with nicotine replacement therapy of smokers who have previously used nicotine replacement therapy has been only somewhat successful. One study showed abstinence rates between 0% and 5% after 6 months, 4 whereas a second study reported that repeated cessation attempts with nicotine replacement therapy resulted in abstinence rates significantly better than placebo. However, the absolute cessation rates (6.4%) after 6 months were quite low. 5 Bupropion sustained release (bupropion SR) is the first non-nicotine-based medication for smoking cessation. Little is known about the impact of previous cessation attempts on the efficacy of bupropion SR. However, a recent retrospective analysis of a placebocontrolled study suggests that bupropion SR shows efficacy rates that are equivalent in both smokers who have used nicotine replacement therapy previously and those who have not.* The effect of repeated use of bupropion SR on abstinence rates has not been studied previously.
We conducted a double-blind, placebo-controlled randomized study to measure the safety and efficacy of a 12-week course of bupropion SR for smoking cessation in smokers who had used bupropion previously in an attempt to stop smoking.
METHODS

Participants.
To be eligible for enrollment, adult participants (≥18 years) were required to have smoked at least 15 cigarettes per day during the previous month, to have exhaled air carbon monoxide (CO) levels greater than 10 ppm (measured with a Smokerlyzer monitor; Bedfont Scientific Ltd, Rochester, Kent, UK), to be motivated to stop smoking, and to have not had more than 24 hours' abstinence during the previous month. Participants were required to have used bupropion as an aid to smoking cessation for at least 2 weeks without experiencing serious adverse events. Participants were excluded if they were predisposed to seizure, had a history of bulimia or anorexia nervosa, had a history of severe renal, hepatic, neurologic, or chronic pulmonary disease, had a current diagnosis of major depression, or were currently using another treatment for smoking cessation. One participant per household was permitted to enter the study. The study was performed in compliance with Institutional Review Board or Independent Ethics Committee regulations and in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
Study design. This was a multicenter, randomized, parallel-group, double-blind placebo-controlled study performed at 16 centers in the United States. The study consisted of a screening phase, a 12-week treatment phase, and a follow-up at month 6.
During the screening phase, participants were assessed for inclusion criteria. Each participant provided a tobacco use history, including the Fagerström Tolerance Questionnaire, 6 and the exhaled CO levels of each subject were measured. Each participant was given a diary to record the number of cigarettes smoked each day and was asked to select a "target quit day" for smoking cessation. A baseline visit was scheduled for 8 days before the target quit day to allow for a minimum of 7 days of treatment before the participant attempted to stop smoking. Participants who satisfied the inclusion criteria were randomized to the treatment phase and received either bupropion SR (150 mg daily on days 1 through 3 and then 150 mg twice daily for the remainder of the 12-week treatment period) or matching placebo. Eligible participants were assigned a protocol-specific treatment number on the basis of a randomization code provided by GlaxoWellcome. Participants at each site received brief individual counseling from trained research counselors based on a standard intervention (ZybanAdvantage Plan) to encourage smoking cessation and to prevent relapse. Participants were instructed not to stop smoking until their target quit day. Participants visited the clinic at weeks 1 through 7, 9, and 12. At each clinic visit smoking status was assessed, abstinence was confirmed by exhaled CO levels ≤10 ppm, and a trained counselor provided a brief individual counseling session. Adverse events were documented, and study medication was dispensed to last until the next visit. Participants completed diaries to record the daily number of cigarettes smoked during the treatment phase. Participants who completed the treatment phase were eligible to enter the follow-up phase (week 13 through month 6). At months 4 and 5 during the follow-up phase, participants received counseling on the telephone. Participants visited the clinic at month 6 for assessment of smoking status and verification of abstinence by measurement of exhaled CO levels.
Outcomes. The primary end point was continuous abstinence from the start of week 4 to the end of week 7. Continuous abstinence was defined as a participant report of no smoking, not even a single puff (on both daily diary and smoking status assessment), confirmed by expired CO ≤10 ppm.
Secondary end points were continuous abstinence from the start of week 9 to the end of week 12 and from the start of week 4 to the end of week 26 as defined for the primary end point. Abstinence was verified with expired CO levels at weeks 9 and 12, which were the remaining clinic visits during the treatment phase. Point prevalence abstinence (abstinence from smoking for the previous 7 days) was assessed at each clinic visit throughout the treatment phase and at the follow-up visit at month 6. Continuous abstinence rates were also calculated from day 22 through each clinic visit during the treatment phase.
Analysis. The intent-to-treat method consisted of all participants who were randomized to treatment. All participants who received at least 1 dose of study medication were included in the safety analysis. For the purposes of analysis, all participants who stopped participating in the study during the treatment phase were considered to be smokers.
The study was powered to detect a difference in the primary end point. The assumptions made for predicting the appropriate sample size were a test size of 0.05, a power of 0.8, a 2-sided alternative hypothesis, and abstinence rates of 20% in the placebo group and 35% in the bupropion SR group. With these assumptions, Fleiss' sample-size calculation 7 returned sample sizes of 200 participants per group.
Rates of continuous abstinence for bupropion SR versus placebo were examined between sites by comparison of treatment-specific rates within each site. Before the data were pooled, we obtained a formal statistical comparison of the between-treatment group difference with use of the Cochran-Mantel-Haenszel test to control for within-site differences.
Data were analyzed with SAS(R) (version 6.12, SAS Institute, Cary, NC). The statistical testing of the null hypothesis (no treatment effect) involved several outcome variables. To manage inflation in the rate of false-positive findings, the set of outcome variables was divided into families of outcome variables ranked according to clinical importance. We controlled for type I error rate by performing statistical tests sequentially and within each family. The families of outcome variables were (1) the primary outcome variable, (2) other abstinence-related variables, and (3) participants' weight and cigarette counts. The primary variable was tested with the Cochran-Mantel-Haenszel test. We controlled for the within-family type I error rate for the other abstinence variable by using resampling methods, 8 and other variables were tested by use of ANOVA.
Subgroup analyses were performed on the participants who were continuously abstinent during weeks 4 through 7 to identify variations in responses within discrete populations. Relative risk estimates were calculated for age, sex, duration of last bupropion SR treat- ment, and outcome of last bupropion SR treatment (abstinence for ≤28 days or >28 days).
RESULTS
Participant characteristics.
Four hundred fifty participants were enrolled in the study and comprised the intent-to-treat population (Table I) . Of these, 224 participants were randomized to receive placebo and 226 to receive bupropion SR. Both treatment groups were comparable in terms of sex, race, and age. Participants in each treatment group also had similar histories for duration of smoking, number of previous cessation attempts, and methods used in these attempts. Most participants had previously used the nicotine patch (58% in the bupropion SR group and 62% in the placebo group) or nicotine gum (39% in the bupropion SR group and 41% in the placebo group), and more than one fourth of the participants in each treatment group had also used hypnotism therapy in a previous cessation attempt (26% in the bupropion SR group and 28% in the placebo group). All participants had used bupropion in at least 1 previous attempt to stop smoking, and the outcomes of these attempts were similar in both treatment groups (Table I) .
Efficacy measures. Because the treatment phases for smoking cessation studies have varied between 7 and 12 weeks, our analyses included abstinence rates for both weeks 4 through 7 and weeks 9 through 12. The rates of continuous abstinence from the start of week 4 through the end of week 7 differed significantly between treatment groups (P < .001). In the bupropion SR group, 27% (61 of 226) of participants remained abstinent throughout the period from weeks 4 through 7 compared with 5% (11 of 224) of participants receiving placebo. Similarly, significantly more participants receiving bupropion SR were continuously abstinent between weeks 9 through 12 compared with participants receiving placebo (64 of 226 [28%] in the bupropion SR group and 20 of 224 [9%] in the placebo group; P < .001). Significantly more participants receiving bupropion SR also remained continuously abstinent throughout the period from weeks 4 through 26 compared with participants receiving placebo (27 of 226 [12%] in the bupropion SR group and 5 of 224 [2%] in the placebo group; P < .001).
Continuous abstinence rates from the start of week 4 through subsequent treatment phase visits were significantly higher in participants receiving bupropion SR than in those taking placebo (P < .001 for clinic visits at weeks 5, 6, 7, 9, 12, and 26; Fig 1) .
Point prevalence rates were consistently higher in the bupropion SR group than in the placebo group during the treatment phase (Fig 2) . Bupropion SR was significantly superior to placebo at all clinic visits from week 2 through week 12 and at week 26 (P ≤ .002 for each visit). At week 26, the point prevalence rates were 21% for bupropion SR and 10% for placebo.
Subgroups analysis. An analysis of continuous abstinence from weeks 4 through 7 was performed for the following subgroups: sex, age, duration of last treatment with bupropion SR, and outcome of last treatment with bupropion SR (Table II) . Male participants receiving bupropion SR had higher overall rates of abstinence and showed a greater difference between treatment and placebo than women taking bupropion SR (odds ratios [OR], 10.4 for men and 4.4 for women). Participants taking bupropion SR who were ≥45 years had higher overall abstinence rates and showed a greater difference between treatment and placebo than younger smokers taking bupropion SR (OR, 13.4 for ≥45 years and 4.4 for <45 years).
Among participants receiving bupropion SR, those whose previous use of bupropion SR had been for 7 weeks or longer showed higher overall abstinence rates and greater improvement over placebo than those whose previous use of bupropion SR had been for less than 7 weeks (OR, 7.4 for ≥7 weeks of use and 6.9 for <7 weeks of use). Finally, participants who had not smoked cigarettes for more than 28 days with their previous use of bupropion SR had higher overall rates of abstinence with both placebo and bupropion SR than participants whose previous use of bupropion SR had Eleven participants receiving placebo (5%) and 19 participants receiving bupropion SR (8%) stopped taking the study medication because of an adverse event.
In participants receiving bupropion SR, the most frequent adverse events that led to discontinuation of treatment were anxiety (n = 4 [2%]), dry mouth (3 [1%]), and rash (3 [1%] ). In participants taking placebo, depression (3 [1%] ) and insomnia (3 [1%] ) were the most frequent adverse events that led to discontinuation of treatment. Four serious adverse events were reported in participants receiving bupropion SR. These were stress incontinence, hernia, and appendicitis, which was considered to be unrelated to study medication, and rash associated with pruritus and edema, which was considered to be related to study medica- tion. In participants taking placebo, there were 2 serious adverse events reported-a gastrointestinal hemorrhage and a paroxysmal atrial fibrillation-neither of which was considered to be related to study medication. There was no significant effect on systolic blood pressure, diastolic blood pressure, or heart rate in either of the treatment groups during the treatment phase.
DISCUSSION
This is the first prospective study to assess the efficacy of retreatment of smokers with bupropion SR who have previously used bupropion in an unsuccessful attempt to quit smoking. The proportion of smokers who have attempted to quit smoking has increased with the availability of pharmacologic aids such as bupropion SR or nicotine replacement therapy. Successful smoking cessation may be viewed as a process rather than a discrete event. For example, the average successful quitter has tried to quit smoking an average of 6 times. 9 Approximately 30% of smokers who receive bupropion SR are still not smoking at the end of 1 year. 9 Similarly, 18% to 30% of smokers who receive nicotine replacement therapy are still not smoking at the end of the 1 year. 9 However, little is known about the efficacy of retreatment of smokers with a pharmacologic aid after an unsuccessful attempt to quit. Understanding the impact of previous cessation attempts, and specifically the medications used, is important in deciding which medications may prove to be successful in future attempts to quit.
To date, 4 studies have examined the efficacy of retreatment of smokers who had previously failed to stop smoking using nicotine replacement therapy. In 3 of these studies, retreatment with transdermal nicotine 4, 5 or with nicotine nasal spray or a nicotine inhaler 3 yielded 6-month continuous abstinence rates of 0% to 6.4%. In contrast, the 6-month continuous abstinence rate in the current study was 12%. In addition, our data and an analysis of data from another recent bupropion study* have suggested equivalent efficacy in both smokers who have previously attempted to stop smoking using nicotine replacement therapy and smokers who have not used nicotine replacement therapy.
Participants in the nicotine replacement therapy retreatment studies typically had 3 to 5 scheduled clinic visits during their treatment with nicotine replacement therapy, and in 2 of these studies, participants also received psychologic behavioral support at each clinic visit. 3, 5 In our study and in the analysis of bupropion SR in participants who had previously failed to quit smoking with nicotine replacement therapy, the frequency of clinic visits that included counseling was higher with 9 visits during the 12-week treatment phase and weekly visits throughout the 8-week treatment phase, respectively. Recent guidelines have emphasized the relationship between the intensity of counseling and its effectiveness. 1 Therefore the relatively low frequency of clinic visits and counseling provided in the nicotine replacement therapy retreatment studies may have contributed to the low rates of abstinence. [3] [4] [5] Abstinence rates for participants receiving placebo were only 3% for weeks 4 through 12, in contrast with placebo abstinence rates in previous bupropion studies that ranged from 12% to 15% at 3 months. 10, 11 Even though participants and the site staff were blinded to the drug assignments and the site staff did not encourage participants to speculate on their assignments, the lower placebo abstinence rates in the current study may be attributable to the previous experiences of participants with bupropion in their previous cessation attempts. Despite the lower placebo abstinence rates, there were no significant differences in participation in the intervention by treatment group (169 of 226 for the bupropion SR group [75%]; 144 of 224 for the placebo group [64%]). This finding suggests that randomization to placebo had little effect on study completion.
Bupropion SR treatment for nicotine dependence is associated with an age ≥45 years, male sex, and a duration of previous therapy >7 weeks. The positive association of smoking cessation with duration of previous bupropion therapy implies that smokers who remain in an initial treatment longer are more likely to be more successful in achieving abstinence when they receive retreatment. The difference between participants assigned to bupropion SR and those assigned to placebo remained significant regardless of the length of previous treatment with bupropion.
The length of a previous attempt to quit (longer) has been correlated with future cessation success, 12 and data from this study support that notion. Participants who remained abstinent for longer than 28 days in their previous smoking cessation attempts with bupropion achieved higher abstinence rates in both active and placebo treatment groups in this study. In conclusion, bupropion SR is an effective medication for retreatment of smokers who have been unsuccessful in previous attempts to quit regardless of the previous smoking cessation medication used. *Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, Nides MA, Ascher JA, Johnston JA. Impact of previous nicotine replacement therapy on the efficacy of bupropion SR, nicotine transdermal system, and combination therapy for smoking cessation. In preparation and on file at GlaxoWellcome Inc.
